Literature DB >> 9089955

Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

D C Montefiori1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9089955     DOI： 10.1007/bf00813504

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  175 in total

Review 1.  Glycobiology.

Authors:  T W Rademacher; R B Parekh; R A Dwek
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

2.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

Authors:  L A Lasky; G Nakamura; D H Smith; C Fennie; C Shimasaki; E Patzer; P Berman; T Gregory; D J Capon
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

3.  AIDS-associated non-Hodgkin lymphoma.

Authors:  V Beral; T Peterman; R Berkelman; H Jaffe
Journal:  Lancet       Date:  1991-04-06       Impact factor: 79.321

Review 4.  Candidate AIDS vaccines.

Authors:  B S Graham; P F Wright
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

5.  Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor.

Authors:  M M Lederman; S F Purvis; E I Walter; J T Carey; M E Medof
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

6.  Circulating levels of mannose binding protein in human immunodeficiency virus infection.

Authors:  G Senaldi; E T Davies; M Mahalingam; J Lu; A Pozniak; M Peakman; K B Reid; D Vergani
Journal:  J Infect       Date:  1995-09       Impact factor: 6.072

7.  Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus.

Authors:  W J Morrow; M Wharton; R B Stricker; J A Levy
Journal:  Clin Immunol Immunopathol       Date:  1986-09

8.  Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.

Authors:  F D Veronese; A L DeVico; T D Copeland; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

9.  Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.

Authors:  D C Montefiori; R J Cornell; J Y Zhou; J T Zhou; V M Hirsch; P R Johnson
Journal:  Virology       Date:  1994-11-15       Impact factor: 3.616

10.  Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55).

Authors:  H Stoiber; C Pintér; A G Siccardi; A Clivio; M P Dierich
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307
View more
  27 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

3.  Antiviral antibodies are necessary for control of simian immunodeficiency virus replication.

Authors:  Christopher J Miller; Meritxell Genescà; Kristina Abel; David Montefiori; Donald Forthal; Kristen Bost; Jun Li; David Favre; Joseph M McCune
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

4.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

5.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

6.  Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis.

Authors:  Lautaro G Perez; Susan Zolla-Pazner; David C Montefiori
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

7.  Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.

Authors:  I Ourmanov; M Bilska; V M Hirsch; D C Montefiori
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis.

Authors:  V Maréchal; M C Prevost; C Petit; E Perret; J M Heard; O Schwartz
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein.

Authors:  Silvija I Staprans; Ashley P Barry; Guido Silvestri; Jeffrey T Safrit; Natalia Kozyr; Beth Sumpter; Hanh Nguyen; Harold McClure; David Montefiori; Jeffrey I Cohen; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

10.  Human erythrocytes selectively bind and enrich infectious HIV-1 virions.

Authors:  Zoltan Beck; Bruce K Brown; Lindsay Wieczorek; Kristina K Peachman; Gary R Matyas; Victoria R Polonis; Mangala Rao; Carl R Alving
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.